Lucid Diagnostics Completes Public Offering for $26.9 Million

Lucid Diagnostics ( (LUCD) ) has shared an update.

On September 11, 2025, Lucid Diagnostics Inc. announced the closing of its underwritten public offering of 28,750,000 shares of common stock at $1.00 per share, generating approximately $26.9 million in net proceeds. The funds are intended for working capital and general corporate purposes, with Canaccord Genuity LLC and BTIG, LLC acting as joint bookrunners, and Maxim Group LLC as co-manager. This offering, made under an existing shelf registration, aims to strengthen Lucid’s financial position and support its ongoing operations in the cancer prevention diagnostics market.

The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.

Spark’s Take on LUCD Stock

According to Spark, TipRanks’ AI Analyst, LUCD is a Neutral.

Lucid Diagnostics’ overall stock score is primarily influenced by its financial performance, which is challenged by negative margins and high leverage. The earnings call provides a cautiously optimistic outlook with significant revenue growth and strategic partnerships. However, technical analysis and valuation indicate potential risks, with mixed signals and a negative P/E ratio.

To see Spark’s full report on LUCD stock, click here.

More about Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, specifically targeting patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer. The company offers the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, which are designed for early detection of esophageal precancer in at-risk patients.

Average Trading Volume: 1,247,923

Technical Sentiment Signal: Buy

Current Market Cap: $110.6M

Learn more about LUCD stock on TipRanks’ Stock Analysis page.